ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated August 12, 2021, with the report signed August 16, 2021. The filing reports a facility lease amendment and changes to the Board of Directors. It does not provide quarterly or annual financial results.
Key Financial and Operating Matters
- The Company expanded its South San Francisco facility by approximately 340 rentable square feet.
- The lease term was extended from May 15, 2022, to May 15, 2028, with a Company option to extend for an additional year.
- The Company must replace its existing security deposit with a letter of credit totaling $467,778.70.
- The landlord will contribute $1,514,835 toward planned facility improvements.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or cash balance figures.
Material Changes and Management Actions
- Director Peter Svennilson voluntarily resigned on August 13, 2021. The filing states that the resignation did not result from any disagreement with the Company or its Board.
- Steven L. Hoerter was appointed as a Class II director, with a term expiring at the 2022 annual meeting, and joined the Audit Committee.
- Mr. Hoerter will receive annual cash retainers of $35,000 for Board service and $7,500 for Audit Committee service.
- He received an option to purchase 33,250 shares of common stock. The option vests monthly over 36 months, subject to continued service, and vests in full upon a qualifying change in control.
Outlook, Risks, Contingencies, and Unusual Items
The filing contains no financial guidance or operating outlook. Material commitments include the long-term facility lease, the required letter of credit, and planned facility improvements. The filing does not state the total future lease obligation or the accounting impact of the landlord contribution. Board compensation and equity award terms may affect future operating expenses and shareholder dilution.
Investor Verification Items
- Review Exhibit 10.1 for the complete lease economics, renewal option, rent schedule, and improvement obligations.
- Confirm the timing and terms of the required $467,778.70 letter of credit.
- Assess the accounting treatment and timing of the $1,514,835 landlord improvement contribution.
- Review the Company’s subsequent filings for the financial impact of the lease and facility expansion.
- Verify the vesting terms and potential dilution associated with the 33,250-share director option.
- Note the filing’s date references: the lease amendment is dated August 12, while the director changes occurred August 13 and the related press release was dated August 16, 2021.